Androgen receptor-independent prostate cancer: an emerging clinical entity

Ilyas SahinDivision of Hematology-Oncology, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, USA

Anthony E. MegaDivision of Hematology-Oncology, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, USA

Benedito A. CarneiroDivision of Hematology-Oncology, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, USACorrespondence[email protected]

References

Saraon P, Drabovich AP, Jarvi KA, Diamandis EP. Mechanisms of androgen-independent prostate cancer. EJIFCC. 2014;25(1):42–54.
PubMedGoogle Scholar
Shukla S, Cyrta J, Murphy DA, Walczak EG, Ran L, Agrawal P, Xie Y, Chen Y, Wang S, Zhan Y, et al. Aberrant activation of a gastrointestinal transcriptional circuit in prostate cancer mediates castration resistance. Cancer Cell. 2017;32(6):792–806. doi:10.1016/j.ccell.2017.10.008.
PubMed Web of Science ®Google Scholar
Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32(4):474–489 e476. doi:10.1016/j.ccell.2017.09.003.
PubMed Web of Science ®Google Scholar
Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004;64(24):9209–9216. doi:10.1158/0008-5472.CAN-04-2442.
PubMed Web of Science ®Google Scholar
Cattrini C, Zanardi E, Vallome G, Cavo A, Cerbone L, Di Meglio A, Fabbroni C, Latocca MM, Rizzo F, Messina C,et al. Targeting androgen-independent pathways: new chances for patients with prostate cancer? Crit Rev Oncol Hematol. 2017;118:42–53. doi:10.1016/j.critrevonc.2017.08.009.
PubMed Web of Science ®Google Scholar
Vandekerkhove G, Chi KN, Wyatt AW. Clinical utility of emerging liquid biomarkers in advanced prostate cancer. Cancer Genet. 2017. pii:S2210-7762(17):30303-4. doi:10.1016/j.cancergen.2017.08.003.
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Androgen receptor-independent prostate cancer: an emerging clinical entity

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Androgen receptor-independent prostate cancer: an emerging clinical entity

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date